Dosimetry-personalised PRRT instead of four fixed cycles
Measure the radiation each patient's tumour and kidneys actually absorb and adjust the number and size of doses, instead of giving everyone four identical cycles.
Overview
The idea is to personalise peptide receptor radionuclide therapy with lutetium-177 dotatate or 177Lu-edotreotide by measuring the radiation each patient's tumour, kidneys and marrow actually absorb on SPECT/CT after each cycle, and adjusting the number and size of doses. The standard of 7.4 GBq for four cycles leaves many patients under-dosed relative to renal and marrow limits, uptake varies widely, and retrospective dosimetry shows tumour absorbed dose correlates with response. The hypothesis is that dosimetry-guided PRRT raises cumulative tumour dose and response rate without exceeding organ limits. The test is a randomised phase 2 of individualised versus fixed activity; P-PRRT in Canada is already testing this, and the idea addresses the wrong-doses bottleneck.
Similar pages
not linked directly; found by shared links- TrialCOMPETE
Shares Grade 3 well-differentiated neuroendocrine tumour, 177Lu-edotreotide, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours.
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares 177Lu-edotreotide, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Peptide receptor radionuclide therapy (PRRT).
- TrialStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Shares Grade 3 well-differentiated neuroendocrine tumour, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Lutetium-177 dotatate.
- IdeaTotal-body PET for personalised radioligand dosing
Shares Fixed versus personalised (dosimetry-guided) dosing, Wrong doses, Dosimetry standardisation for radioligand therapy, Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Grade 3 well-differentiated neuroendocrine tumour, Dosimetry, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours.
- CompanyMolecular Targeting Technologies
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate.
- TrialLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Shares Grade 3 well-differentiated neuroendocrine tumour, 177Lu-edotreotide, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours.
- TrialNETTER-1
Shares Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Peptide receptor radionuclide therapy (PRRT).